CO5370684A1 - Anticuerpos humanos que se unen a mn y tienen actividad neutralizante de la adhesion celular - Google Patents

Anticuerpos humanos que se unen a mn y tienen actividad neutralizante de la adhesion celular

Info

Publication number
CO5370684A1
CO5370684A1 CO02094163A CO02094163A CO5370684A1 CO 5370684 A1 CO5370684 A1 CO 5370684A1 CO 02094163 A CO02094163 A CO 02094163A CO 02094163 A CO02094163 A CO 02094163A CO 5370684 A1 CO5370684 A1 CO 5370684A1
Authority
CO
Colombia
Prior art keywords
antibodies
human
polynucleotides
cell adhesion
preparation
Prior art date
Application number
CO02094163A
Other languages
English (en)
Spanish (es)
Inventor
Takeuchi Toshihiko
Nathalie Dubois-Strin
John E Murphy
Julie Rinkenberger
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp filed Critical Bayer Corp
Publication of CO5370684A1 publication Critical patent/CO5370684A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3038—Kidney, bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CO02094163A 2001-10-18 2002-10-18 Anticuerpos humanos que se unen a mn y tienen actividad neutralizante de la adhesion celular CO5370684A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34365701P 2001-10-18 2001-10-18
US37771602P 2002-05-02 2002-05-02

Publications (1)

Publication Number Publication Date
CO5370684A1 true CO5370684A1 (es) 2004-02-27

Family

ID=26993561

Family Applications (1)

Application Number Title Priority Date Filing Date
CO02094163A CO5370684A1 (es) 2001-10-18 2002-10-18 Anticuerpos humanos que se unen a mn y tienen actividad neutralizante de la adhesion celular

Country Status (18)

Country Link
US (2) US7462696B2 (enExample)
EP (1) EP1438339A4 (enExample)
JP (2) JP2005528884A (enExample)
KR (1) KR20050037478A (enExample)
CN (1) CN1606569A (enExample)
AR (1) AR036833A1 (enExample)
BR (1) BR0213968A (enExample)
CA (1) CA2463943A1 (enExample)
CO (1) CO5370684A1 (enExample)
DO (1) DOP2002000494A (enExample)
HU (1) HUP0600335A2 (enExample)
IL (1) IL161411A0 (enExample)
MX (1) MXPA04003508A (enExample)
PE (1) PE20030473A1 (enExample)
PL (1) PL374304A1 (enExample)
RU (1) RU2317998C2 (enExample)
UY (1) UY27499A1 (enExample)
WO (1) WO2003033674A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040191246A1 (en) * 2003-02-26 2004-09-30 Connelly Patrick R. Process for in vivo treatment of specific biological targets in bodily fluid
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US20090162382A1 (en) * 2002-03-01 2009-06-25 Bernett Matthew J Optimized ca9 antibodies and methods of using the same
US7504364B2 (en) 2002-03-01 2009-03-17 Receptors Llc Methods of making arrays and artificial receptors
US7469076B2 (en) 2003-09-03 2008-12-23 Receptors Llc Sensors employing combinatorial artificial receptors
EP1613737A4 (en) 2003-03-28 2008-12-03 Receptors Llc ARTIFICIAL RECEPTORS COMPRISING REVERSIBLE IMMOBILIZED CONSTRUCTION BLOCKS AND METHODS
EP1664778A2 (en) * 2003-09-03 2006-06-07 Receptors LLC Nanodevices employing combinatorial artificial receptors
US7504365B2 (en) 2004-09-03 2009-03-17 Receptors Llc Combinatorial artificial receptors including tether building blocks
US7985715B2 (en) 2004-09-11 2011-07-26 Receptors Llc Combinatorial artificial receptors including peptide building blocks
DOP2006000277A (es) * 2005-12-12 2007-08-31 Bayer Pharmaceuticals Corp Anticuerpos anti mn y métodos para su utilización
US20140273033A1 (en) * 2007-04-12 2014-09-18 Universiteit Hasselt Biomarkers for multiple sclerosis
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
HUE029003T2 (en) * 2008-05-30 2017-01-30 Xbiotech Inc IL-1 alpha antibodies
DK2839860T3 (da) 2012-10-12 2019-06-17 Medimmune Ltd Pyrrolobenzodiazepiner og konjugater deraf
ES2687439T3 (es) 2013-03-13 2018-10-25 Medimmune Limited Pirrolobenzodiazepinas y conjugados de las mismas
EP4001920A1 (en) * 2014-04-03 2022-05-25 AllerGenis, LLC Peptides and methods for detecting food allergy
EP3193940A1 (en) 2014-09-10 2017-07-26 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
CN109862919A (zh) 2016-10-11 2019-06-07 免疫医疗有限公司 抗体-药物缀合物联合免疫介导的治疗剂
CA3098103A1 (en) 2018-05-23 2019-11-28 Adc Therapeutics Sa Molecular adjuvant
US20230372528A1 (en) 2020-10-16 2023-11-23 University Of Georgia Research Foundation, Inc. Glycoconjugates
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
CN117980327A (zh) 2021-11-03 2024-05-03 杭州多禧生物科技有限公司 抗体的特异性偶联

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP1690935A3 (en) * 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6297051B1 (en) * 1997-01-24 2001-10-02 Institute Of Virology, Slovak Academy Of Sciences MN gene and protein
WO1995034650A2 (en) * 1994-06-15 1995-12-21 Ciba Corning Diagnostics Corp. Mn gene and protein
AU758957C (en) * 1998-10-23 2004-08-12 Institute Of Virology Of The Slovak Academy Of Sciences MN gene and protein
US6689744B2 (en) * 2000-09-22 2004-02-10 Genentech, Inc. Notch receptor agonists and uses

Also Published As

Publication number Publication date
PE20030473A1 (es) 2003-06-26
MXPA04003508A (es) 2004-07-22
UY27499A1 (es) 2003-05-30
RU2317998C2 (ru) 2008-02-27
WO2003033674A3 (en) 2003-08-21
CA2463943A1 (en) 2003-04-24
US20100240100A1 (en) 2010-09-23
DOP2002000494A (es) 2004-05-31
AR036833A1 (es) 2004-10-06
PL374304A1 (en) 2005-10-03
IL161411A0 (en) 2004-09-27
JP2010260845A (ja) 2010-11-18
KR20050037478A (ko) 2005-04-22
US7462696B2 (en) 2008-12-09
WO2003033674A2 (en) 2003-04-24
CN1606569A (zh) 2005-04-13
BR0213968A (pt) 2005-05-10
EP1438339A2 (en) 2004-07-21
HUP0600335A2 (en) 2006-08-28
US20030077277A1 (en) 2003-04-24
JP2005528884A (ja) 2005-09-29
EP1438339A4 (en) 2008-08-27
RU2004115112A (ru) 2005-04-27

Similar Documents

Publication Publication Date Title
AR036833A1 (es) Anticuerpos humanos que se unen a mn y tienen actividad neutralizante de la adhesion celular.
CO2022013525A2 (es) Anticuerpos contra sars-cov-2 y métodos para usarlos
CL2022003747A1 (es) Anticuerpos ccr8 para aplicaciones terapéuticas
CY1123400T1 (el) Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
PE20050712A1 (es) Anticuerpos rg1
CR10143A (es) Antígenos de ácido des-n-acetil-siálico, anticuerpos para los mismos y métodos de uso en la terapia del cáncer
CO6351751A2 (es) Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
CY1118549T1 (el) Χρηση anti-vegf αντισωματος σε συνδυασμο με χημειοθεραπεια για τη θεραπευτικη αγωγη του καρκινου του μαστου
BR112021024544A2 (pt) Anticorpo monoclonal anti-ceacam5 e método de preparação do mesmo e uso do mesmo
AR063086A1 (es) Anticuerpos humanos que se unen a cxcr4 y usos de los mismos
ATE526037T1 (de) Verfahren zum abtöten von tumorzellen mittels targeting von auf apoptotischen tumorzellen exponierten internen antigenen
PE20071055A1 (es) Anticuerpos anti mn
AR046068A1 (es) Anticuerpos de factor tisular y uso de los mismos
EA201491977A1 (ru) Молекула антитела к gcc и ее применение для тестирования на чувствительность к gcc-нацеленной терапии
BR0116763A (pt) Anticorpos humanos especìficos para terapia seletiva do c ncer
ES2090052T3 (es) Anticuerpos monoclonales (mak) contra antigenos asociados a tumores, su preparacion y uso.
ES2570627T3 (es) Ensayo in vitro de Ezrina para el diagnóstico del cáncer colorrectal
DOP2009000208A (es) Métodos de tratamiento del cáncer mediante administración de combinaciones de il-18 humana
MA32288B1 (fr) Nouveaux anticorps utiles pour le traitement du cancer
BRPI0407680A (pt) métodos para diagnóstico de cáncer e diminuição de metástase por células cancerosas
CO2023009100A2 (es) Anticuerpos biespecíficos contra ceacam5 y cd47
ES2173910T3 (es) Anticuerpos humanizados dirigidos contra el antigeno a33.
ECSP024340A (es) Anticuerpos humanos que se unen a mn y tienen actividad neutralizante de la adhesion celular
AR077941A1 (es) Anticuerpos contra osteopontina
EA200600995A1 (ru) Молекулы, ингибирующие ангиогенез, и их применение в лечении и диагностике рака